Funding UBE: 1 954 804 €
Duration: 2024-2028
Scientific leader ICMUB: DENAT Franck
Summary
Metastatic colorectal cancer (mCRC) and metastatic gastric cancer (mGC) are among the most aggressive cancers, for which current therapeutic strategies remain insufficient. The administration of radiopharmaceuticals to specifically deliver radioactive isotopes to a tumor-associated target appears to be a promising approach, combining diagnosis and therapy (theranostics) for these types of disseminated cancers. The COMETE project aims to develop theranostic molecules by chemically modifying proteins capable of specifically recognizing tumor targets, by grafting a radionuclide-chelating agent for therapeutic purposes (targeted radionuclide therapy, TRT) and diagnostic purposes (diagnostic companion).
Our project is structured around four objectives:
- Identification and validation of tumor targets
- Development of new TRT molecules to treat mCRC and mGC
- Evaluation in preclinical models of the antitumor efficacy and toxicity of the TRT molecules depending on the radionuclide
- Development of companion imaging agents to select responding patients, determine the optimal dose, and monitor the effectiveness of TRT.
This project paves the way for the development of new personalized medicine approaches to enhance therapy effectiveness while minimizing potential side effects.
Total UE funding : 1 954 804 €
Partners:
- OPM Oncodesign Precision Medicine (Responsable scientifique : Dr. Alexia DAOUST)
- CGFL Centre Georges François Leclerc (Responsables scientifiques : Pr. Alexandre COCHET, Dr. Pierre-Simon BELLAYE)